Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Core Points - Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases [3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 [1] - The most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [3] - Bezuclastinib is designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) [3] - Cogent is also developing a portfolio of targeted therapies for mutations in FGFR2, ErbB2, PI3Kα, and KRAS [3] Company Information - Cogent Biosciences is headquartered in Waltham, MA, and Boulder, CO [3] - The company provides a live webcast of its presentations on its Investors & Media page [2] - A replay of the webcast will be available for 30 days after the event [2] Contact Information - Christi Waarich is the Senior Director of Investor Relations [4] - Contact details include email: christi.waarich@cogentbio.com and phone: 617-830-1653 [4]